Overview
Pharmaceutical

Nippon Shinyaku Co.,Ltd.

Nippon Shinyaku is a Japanese pharmaceutical and functional food company focused on developing and commercializing treatments for rare and intractable diseases using proprietary technologies. Its pharmaceutical business spans drug discovery, development, and sales, including specialty areas such as pulmonary arterial hypertension and hematologic malignancies, with an expanding global pipeline through licensing and collaborative research. Its functional food business leverages pharmaceutical-grade quality standards to offer health-oriented consumer products.

Market Cap
¥231B
US$1.48B
EV
¥106B
US$676M
Stock¥3,432▲+0.20%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
2.4
x
LTM EV/EBIT
2.8
x
LTM PER
7.3
x
LTM PBR
0.8
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-18.0%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Dec 4, 25Bain Capital MBO announcement (110B yen)
MC → EV Bridge
231BUS$1.48BMarket Cap2.56BUS$16.3M+ Debt72.7BUS$464M− Cash55.5BUS$354M− Inv. Sec.0.32BUS$2.03M+ NCI106BUS$676MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
137US$877M'22/3144US$919M'23/3148US$946M'24/3160US$1.02B'25/3171US$1.09B'26/3
EBITDA 5Y (¥B)
37.5US$239M'22/335.1US$224M'23/338.3US$244M'24/341.5US$264M'25/342.1US$269M'26/3
Net Income 5Y (¥B)
25.0US$159M'22/322.8US$145M'23/325.9US$165M'24/332.6US$208M'25/329.7US$190M'26/3
Capital Structure
99%
EquityD/E 0.01xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
60.6US$386M2.71US$17.3M'22/360.0US$383M2.66US$17.0M'23/358.1US$370M2.87US$18.3M'24/355.2US$352M2.72US$17.4M'25/376.6US$488M2.57US$16.4M'26/3
Shareholders
Top 10 hold 46.6%
1
The Master Trust Bank of Japan, Ltd. (Trust Account)
12.02%
2
Meiji Yasuda Life Insurance Company
9.62%
3
Custody Bank of Japan, Ltd. (Trust Account)
7.30%
4
The Bank of Kyoto, Ltd.
4.58%
5
MUFG Bank, Ltd.
4.02%
6
Nippon Life Insurance Company
1.99%
7
STATE STREET BANK AND TRUST COMPANY 505001 (Standing Proxy: Mizuho Bank, Ltd.)
1.91%
8
THE BANK OF NEW YORK MELLON 140044 (Standing Proxy: Mizuho Bank, Ltd.)
1.74%
9
Morgan Stanley MUFG Securities Co., Ltd.
1.70%
10
STATE STREET BANK AND TRUST COMPANY 505103 (Standing Proxy: Mizuho Bank, Ltd.)
1.69%
Management
16 officers
Shigenobu MAEKAWA
Representative Director, Chairman
Apr 1976 Joined the Company Mar 1992 Seconded to Japan Federation of Employers' Associations Apr 2002 General Manager, Corporate Planning Department, Management Strategy Office Apr 2004 Executive Officer Jun 2005 Director Jun 2005 In charge of Corporate Planning, Accounting and Finance, and Information Systems; concurrently General Manager, Corporate Planning Department Jun 2006 Managing Director Apr 2007 In charge of Corporate Planning, Accounting and Finance, and Information Systems Jun 2007 Representative Director, President Jun 2021 Representative Director, Chairman (current) Jun 2023 Outside Director, Kyocera Corporation (current)
1953-01-18
Toru NAKAI
Representative Director, President
Apr 1995 Joined the Company Apr 2016 General Manager, Business Planning Department Apr 2018 Assigned to Corporate Planning (NS Pharma) Apr 2019 General Manager, International Business Division; concurrently assigned to International Business Division (NS Pharma) Jun 2019 Director Jun 2019 In charge of International Business; concurrently General Manager, International Business Division Jun 2021 Representative Director, President (current)
1971-12-23
Hiroyoshi EDAMITSU
Director, in charge of Corporate Planning and Sustainability
Apr 1989 Joined the Company Aug 2011 General Manager, Corporate Planning Department Apr 2013 Executive Officer; General Manager, Corporate Planning Department Jun 2018 Director (current) Jun 2018 In charge of Corporate Planning Apr 2022 In charge of Corporate Planning and Sustainability (current)
1963-08-08
Hitoshi ISHIZAWA
Director, in charge of Functional Food
Apr 1985 Joined the Company Apr 2013 General Manager, Kita-Kanto Branch, Hokkaido/Tohoku Regional Sales Division Apr 2014 General Manager, Chugoku Branch, Western Japan Regional Sales Division Apr 2015 General Manager, Tokyo Branch, Eastern Japan Regional Sales Division Apr 2017 General Manager, Osaka Branch, Sales Division Apr 2018 Executive Officer; General Manager, Osaka Branch, Sales Division Apr 2021 Executive Officer; General Manager, Kansai Branch, Sales Division Jun 2021 Director (current) Jun 2021 In charge of Functional Food; concurrently Head of Functional Food Company (current)
1961-09-18
Hitomi KIMURA
Director, in charge of Supply Chain and Quality Assurance
Apr 1984 Joined the Company Apr 2015 General Manager, Regulatory Affairs Department, Quality Assurance Division Apr 2020 General Manager, Quality Assurance Division (General Marketing Authorization Holder) Apr 2021 Executive Officer; General Manager, Quality Assurance Division (General Marketing Authorization Holder) Jun 2021 Director (current) Jun 2021 In charge of Supply Chain and Quality Assurance (current)
1961-09-02
Kazuyuki IWATA
Director, in charge of Sales
Apr 1990 Joined the Company Apr 2015 General Manager, Chiba Branch, Eastern Japan Regional Sales Division Apr 2016 General Manager, Yokohama Branch, Eastern Japan Regional Sales Division Apr 2017 General Manager, Primary Care Promotion Department, Sales Planning Division Apr 2019 General Manager, Urology Medical Affairs Department, Sales Planning Division Apr 2021 General Manager, Kan-Etsu Branch, Sales Division Apr 2022 General Manager, Nagoya Branch, Sales Division Apr 2023 Executive Officer; General Manager, Nagoya Branch, Sales Division Jun 2025 Director (current) Jun 2025 In charge of Sales; concurrently General Manager, Sales Division (current)
1966-11-16
Keiichi KUWANO
Director, in charge of Research and Development
Apr 1993 Joined the Company Apr 2016 General Manager, Research Planning Department, Research and Development Planning Division Jun 2021 General Manager, Drug Discovery Research Laboratories, Research and Development Division Apr 2022 Executive Officer; General Manager, Drug Discovery Research Laboratories, Research and Development Division Jun 2025 Director (current) Jun 2025 In charge of Research and Development; concurrently General Manager, Research and Development Division (current)
1967-04-18
Yoshinao WADA
Director
Jul 1975 Joined Osaka University Hospital Nov 1981 Maternal Medicine, Osaka Prefectural Center for Maternal and Child Health Oct 1989 Received Doctor of Medicine degree, Osaka University Apr 1991 Head, Metabolism Division, Research Institute, Osaka Prefectural Center for Maternal and Child Health Apr 1998 Director, Research Institute, Osaka Prefectural Center for Maternal and Child Health Apr 2011 Head, Maternal Medicine Department; concurrently Director, Research Institute, Osaka Prefectural Center for Maternal and Child Health Apr 2014 Chief Department Head, Maternal Medicine Department; concurrently Director, Research Institute, Osaka Prefectural Center for Maternal and Child Health Apr 2016 Part-time Physician, Maternal Medicine Department, Osaka Prefectural Center for Maternal and Child Health Apr 2017 Part-time Physician, Maternal Medicine Department, Osaka Women's and Children's Hospital (current) Apr 2018 Visiting Professor, Yokohama City University Jun 2019 Director of the Company (current)
1950-12-25
Yukari KOBAYASHI
Director
Jun 1987 Joined IBM Japan, Ltd. Jul 2002 General Manager, Division, IBM Japan, Ltd. Jan 2007 Executive Officer... Fellow, IBM Japan, Ltd. Jan 2007 Executive Officer, IBM Business Consulting Services K.K. Mar 2016 Joined Mercer Japan Ltd. Mar 2016 In charge of Growth Strategy; concurrently Head of President's Office, Mercer Japan Ltd. Jan 2018 Director, Mercer Investment Solutions K.K. Feb 2018 Chief Operating Officer, Mercer Japan Ltd. Jul 2018 Joined Microsoft Japan Co., Ltd. Sep 2018 Executive Officer; General Manager, Corporate Strategy Division; concurrently Head of President's Office, Microsoft Japan Co., Ltd. Mar 2020 Representative, Amanda Life Consulting LLC (current) Jun 2021 Director of the Company (current) Apr 2022 Outside Director, Panasonic Connect Co., Ltd. Mar 2023 Outside Director, Bridgestone Corporation (current) Jun 2023 Representative, JC1 LLC (current)
1963-04-17
Mayumi NISHI
Director
Apr 1980 Joined Aichi Cancer Center Research Institute, Department of Biology Apr 1980 Licensed Pharmacist Apr 1991 Joined Department of Anesthesiology, Kyoto Prefectural University of Medicine May 1991 Licensed Physician Mar 1997 Received Doctor of Medicine degree, Kyoto Prefectural University of Medicine Apr 1997 Assistant, Department of Anatomy I, Kyoto Prefectural University of Medicine Jun 1998 Lecturer, Department of Anatomy I, Kyoto Prefectural University of Medicine Apr 2003 Lecturer, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Apr 2005 Associate Professor, Department of Bioscience and Anatomy, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Apr 2007 Associate Professor, Department of Bioscience and Anatomy, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Aug 2009 Professor, Department of Anatomy I, Nara Medical University Apr 2010 Visiting Professor, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Apr 2023 Professor Emeritus, Nara Medical University (current) Jun 2023 Director of the Company (current)
1957-10-07
Yotaro HONGO
Director
Apr 1990 Joined Sanwa Bank, Ltd. May 1995 Received MBA, The Wharton School, University of Pennsylvania Aug 1999 Joined Investment Banking Division, J.P. Morgan Securities Japan Co., Ltd. May 2008 Managing Director, J.P. Morgan Securities Japan Co., Ltd. Jan 2023 Vice Chairman, Investment Banking Division, J.P. Morgan Securities Japan Co., Ltd. May 2025 Resigned from J.P. Morgan Securities Japan Co., Ltd. Jun 2025 Director of the Company (current)
1967-06-14
Koji KOIZUMI
Director
Apr 1990 Joined the Company Apr 2014 General Manager, Product Marketing Department, Sales Planning Division Apr 2015 General Manager, Urology Promotion Department, Sales Planning Division Apr 2017 General Manager, Yokohama Branch, Sales Division Apr 2019 General Manager, Nagoya Branch, Sales Division Apr 2020 Executive Officer; General Manager, Nagoya Branch, Sales Division Apr 2021 Executive Officer; General Manager, Sales Planning Division Apr 2026 Executive Officer, assigned to Human Resources, General Affairs, Risk, Compliance and DX Apr 2026 In charge of Human Resources and DX (current)
Hiroshi ITO
Full-time Audit & Supervisory Board Member
Apr 1986 Joined the Company Apr 2015 General Manager, Kyoto-Shiga/Hokuriku Branch, Western Japan Regional Sales Division Apr 2017 General Manager, Kyushu Branch, Sales Division Apr 2019 General Manager, Chugoku-Shikoku Branch, Sales Division Apr 2021 General Manager, Nagoya Branch, Sales Division Apr 2022 General Manager, Information Provision Activities Supervision Department Jun 2023 Full-time Audit & Supervisory Board Member (current)
1962-05-07
Eriko DOI
Full-time Audit & Supervisory Board Member
Apr 1984 Joined the Company Apr 2007 Manager, Research Planning Promotion Section, Research Planning Department, Research and Development Planning Center, Research and Development Division Apr 2008 Manager, Research Planning Promotion Section, Research Planning Department, Research and Development Planning Division Apr 2016 General Manager, Drug Safety Management Department, Quality Assurance Division Apr 2018 General Manager, Drug Safety Management Department, Quality Assurance Division (Chief Safety Officer) Jun 2024 Full-time Audit & Supervisory Board Member (current)
1961-10-02
Koji HARA
Audit & Supervisory Board Member
Apr 1983 Joined National Tax Agency, Osaka Regional Taxation Bureau Jul 2012 Director, Shingu Tax Office, Osaka Regional Taxation Bureau Jul 2015 Head, International Information Section 2, Investigation Department 1, Osaka Regional Taxation Bureau Jul 2016 Director, Nishi Tax Office, Osaka Regional Taxation Bureau Jul 2017 Head, Investigation Management Section, Investigation Department 1, Osaka Regional Taxation Bureau Jul 2019 Deputy Head, Investigation Department 2, Osaka Regional Taxation Bureau Jul 2020 Director, Kita Tax Office, Osaka Regional Taxation Bureau Jul 2021 Retired from Kita Tax Office, Osaka Regional Taxation Bureau Aug 2021 Registered as Certified Tax Accountant Aug 2021 Principal, Koji Hara Certified Tax Accountant Office (current) Jun 2023 Audit & Supervisory Board Member of the Company (current)
1960-07-14
Mariko CHAKI
Audit & Supervisory Board Member
Sep 2002 Completed Legal Training, Legal Training and Research Institute Oct 2002 Registered with Kyoto Bar Association Oct 2002 Joined Oike Sogo Law Office Oct 2006 Partner Attorney, Oike Sogo Law Office (current) Jun 2024 Audit & Supervisory Board Member of the Company (current) Jun 2026 External Director, Japan Association of University Health Management (current)
1977-09-04
Large Shareholding Reports
Nomura Asset Management Co., Ltd.
2025-12-18
4.67%→5.86%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-06
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-05-29
株主総会招集通知
TDnet
2026-02-09
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-12-18
Large Shareholding Report
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-07
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-07
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-07
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-28
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-14
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-30
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-12
Quarterly Securities Report
EDINET
2022-06-30
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-12
Quarterly Securities Report
EDINETAmended
2021-07-02
Amended Annual Securities Report
EDINET
2021-06-30
Annual Securities Report
EDINET
2021-02-10
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →